Development of a Loop-Mediated Isothermal Amplification Method for Detection of Histoplasma capsulatum DNA in Clinical Samples

Christina M. Scheel, Yitian Zhou, Raquel C. Theodoro, Bethany Abrams, S. Arunmozhi Balajee and Anastasia P. Litvintseva

Published Ahead of Print 27 November 2013.

Updated information and services can be found at:
http://jcm.asm.org/content/52/2/483

These include:

REFERENCES
This article cites 38 articles, 13 of which can be accessed free at:
http://jcm.asm.org/content/52/2/483#ref-list-1

CONTENT ALERTS
Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»

Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to: http://journals.asm.org/site/subscriptions/
Development of a Loop-Mediated Isothermal Amplification Method for Detection of Histoplasma capsulatum DNA in Clinical Samples

Christina M. Scheel,a Yitian Zhou,a** Raquel C. Theodoro,b Bethany Abrams,a** S. Arunmozhi Balajee,c Anastasia P. Litvintseva,a

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Universidade Estadual Paulista, Campus de Botucatu-UNESP, San Paulo, Brazil; Division of Global Disease Detection and Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Improved methods for the detection of Histoplasma capsulatum are needed in regions with limited resources in which the organism is endemic, where delayed diagnosis of progressive disseminated histoplasmosis (PDH) results in high mortality rates. We have investigated the use of a loop-mediated isothermal amplification (LAMP) assay to facilitate rapid inexpensive molecular diagnosis of this disease. Primers for LAMP were designed to amplify the Hcp100 locus of H. capsulatum. The sensitivity and limit of detection were evaluated using DNA extracted from 91 clinical isolates of known geographic subspecies, while the assay specificity was determined using DNA extracted from 50 other fungi and Mycobacterium tuberculosis. Urine specimens (n = 6) collected from HIV-positive individuals with culture- and antigen-proven histoplasmosis were evaluated using the LAMP assay. Specimens from healthy persons (n = 10) without evidence of histoplasmosis were used as assay controls. The Hcp100 LAMP assay was 100% sensitive and specific when tested with DNA extracted from culture isolates. The median limit of detection was ≤6 genomes (range, 1 to 300 genomes) for all except one geographic subspecies. The LAMP assay detected Hcp100 in 67% of antigen-positive urine specimens (4/6 specimens), and results were negative for Hcp100 in all healthy control urine specimens. We have shown that the Hcp100 LAMP assay is a rapid affordable assay that can be used to expedite culture confirmation of H. capsulatum in regions in which PDH is endemic. Further, our results indicate proof of the concept that the assay can be used to detect Histoplasma DNA in urine. Further evaluation of this assay using body fluid samples from a larger patient population is warranted.

Histoplasma capsulatum is a dimorphic fungus that causes histoplasmosis. In immunocompromised persons, H. capsulatum can disseminate throughout the body, causing progressive disseminated histoplasmosis (PDH), which is characterized by fever, weight loss, and hepatosplenomegaly. Without early diagnosis and antifungal intervention, PDH can cause death.

Timely detection of PDH is problematic in resource-challenged countries, since few rapid assays exist for this disease (1) and its symptoms are vague and often confused with those of mycobacterial or leishmanial infections (2, 3). Many laboratories in resource-limited areas in which the disease is endemic rely on sterile-site cultures for diagnosis of PDH; however, H. capsulatum grows slowly and may take several weeks for identification in cultures. The AccuProbe H. capsulatum culture identification test (Gen-Probe) can be used for rapid molecular identification of H. capsulatum in cultures, but this test is expensive and is not readily available in developing countries. Several additional molecular assays for detection of H. capsulatum have been developed (1, 4, 5), but none has been subjected to large-scale interlaboratory evaluation. These assays rely on PCR methodology and require expensive reagents and equipment, which may be unsustainable in laboratories with limited funding.

Here we describe the development of a loop-mediated isothermal amplification (LAMP) assay for histoplasmosis, which provides an affordable method of molecular identification that can be performed and interpreted without costly equipment in resource-challenged regions. Briefly, LAMP is a nucleic acid amplification technique that utilizes a polymerase with helicase activity, Bst from Bacillus stearothermophilus. The helicase activity allows for amplification of DNA at a constant temperature and is facilitated by four primers, 2 with cDNA, that form stem-loop DNA structures. Once formed, the stem-loop structures become the template DNA for further amplification, which occurs very rapidly (6).

Nucleic acid amplification via LAMP has several cost advantages over PCR. First, Bst polymerase is less expensive and more robust than Taq (7–9). Further, LAMP requires no thermal cycling equipment, since the assay is performed at a single temperature, allowing the use of either a heat block or a water bath to achieve nucleic acid amplification. Reactions are carried out in single tubes, and results can be visualized under UV light. In order to facilitate rapid inexpensive molecular diagnosis of PDH, we developed a LAMP assay targeting the single-copy gene Hcp100. Hcp100 is a member of the p100 gene family and is overexpressed in H. capsulatum during macrophage invasion (10). Unlike many multicopy housekeeping genes, Hcp100 shows little sequence identity with the DNA of related organisms and is not prone to false hybridization that may lead to cross-reactivity.

MATERIALS AND METHODS

H. capsulatum isolates. H. capsulatum isolates (n = 91) used in this study were cultured from frozen mycelial stocks provided by Roche Molecular

Received 3 October 2013 Returned for modification 11 November 2013 Accepted 19 November 2013 Published ahead of print 27 November 2013

Address correspondence to Christina M. Scheel, zsr3@cdc.gov. * Present address: Yitian Zhou, University of Pennsylvania Graduate School, Philadelphia, Pennsylvania, USA; Bethany Abrams, Emory University, Atlanta, Georgia, USA.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Systems (Pleasanton, CA). Mycelia were grown on brain heart infusion (BHI) agar slants and subcultured three times to ensure optimal growth and purity prior to DNA extraction. All isolates were previously identified with respect to their geographic subspecies by multilocus sequence typing (MLST) and phylogenetic analysis (11), as described by Theodoro et al. (12). The geographic subspecies of study isolates were as follows: four North American 1 (NAm 1), 65 North American 2 (NAm 2), 11 Latin American A (LAm A), five Latin American B (LAm B), two lineage H81, and one each African, Netherlands, lineage H61, and H68.

**Fungal DNA extraction.** Genomic DNA was extracted using a Qiagen DNeasy tissue kit (Qiagen, Valencia, CA), with several modifications to the manufacturer’s instructions. Briefly, a portion of the fungal mat was transferred to 5-mL polypropylene tubes containing 800 μL Qiagen AT buffer and 60 U of proteinase K and was homogenized inside a biological safety cabinet using an Omni tissue homogenizer (Omni International, Kennesaw, GA) at slow speed for 30 s and then at high speed for 30 s, using a clean probe for each isolate. Homogenates were capped, incubated at 35°C for 1 h with frequent vortex mixing, and then cooled to room temperature (RT). For each homogenate, RNase A (Sigma-Aldrich Corp., St. Louis, MO) was added to a final concentration of 1 mg/mL and the mixture was incubated for 5 min at RT, followed by the addition of 900 μL Qiagen buffer AL and vortex mixing. Homogenates were incubated at 70°C for 10 min, transferred to 1.7-mL microcentrifuge tubes, and centrifuged at 15,000 × g for 10 min. Clear supernatants (1 mL each) were transferred to clean microcentrifuge tubes, and 500 μL of 200 mM (ca. 200) of proteinase-grade ethanol (Sigma-Aldrich Corp.) was added to each tube. The suspensions were vortex mixed and transferred to Qiagen DNeasy columns; the manufacturer’s instructions were followed throughout the remainder of the procedure, except that DNA was eluted with 0.1 M Tris. DNA was quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Archived fungal DNA samples used as controls were buffer exchanged into 0.01 M Tris using the Qiagen protocol for cleanup of genomic DNA (13), in order to eliminate EDTA and other additives known to interfere with subsequent applications.

**PCR and sequencing of the Hcp100 genetic locus.** Portions of the *H. capsulatum* Hcp100 gene were PCR amplified using *H. capsulatum* JCM 1.1 (5′-GGTTCCTGAGCCCTCCACCTGCAGC CGTGATG-3′) and Hc II (5′-ATGTCCCATCGGCGCGCGT CTGC-3′) primers, as described previously (14). Each 25-μL reaction mixture contained 0.2 μL each primer, 0.25 mM MgCl2, 0.2 mM each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxynucleoside triphosphate (dNTP), and 0.625 U (12) Taq DNA polymerase in a buffer of 10 mM Tris (pH 8.3), 50 mM KCl (Roche Carolina each deoxy...
RESULTS

**LAMP assay validity with Histoplasma isolates.** The Hcp100 LAMP assay was able to detect DNA of all geometrically diverse H. capsulatum isolates. The LOD was strain dependent, and values fell between 10 fg/μL and 1 pg/μL (1 to 30 genomes per reaction) of H. capsulatum (Table 3), with a median of 6 genomes. Sixteen strains were detected at concentrations of ≤100 fg/μL (1 to 6 genomes), and 19 were reactive at ≤10 fg/μL (one genome). When Hcp100 LAMP was compared with traditional PCR of Hcp100, the LAMP assay showed a 10-fold lower LOD (data not shown).

The specificity of the LAMP assay was determined by testing the reactivity of LAMP primers against DNA of other clinically relevant yeasts and molds (Table 2), as well as human and mycobacterial DNA. No cross-reactivity occurred with any other organism tested, and the assay was 100% specific. When the assay incubation time was increased from 1.5 to 2 h, however, cross-reactivity did occur with some negative-control DNA samples.

**LAMP assay validity with human urine specimens.** The two mock-positive samples that were prepared by spiking control urine samples with known concentrations of H. capsulatum DNA were assayed using LAMP and conventional PCR. These samples showed strong signals in the LAMP assay, and Hcp100 bands were present with PCR amplification (data not shown).

In addition, we tested six urine samples from persons with HIV infection and proven histoplasmosis (Table 4). Four of these samples (67%) showed strong signals in the Hcp100 LAMP assay, three with fluorescence in both the pellet and supernatant fractions and one with fluorescence in the pellet fraction only (Table 4). None of the 6 samples showed Hcp100 bands when DNA was amplified using traditional PCR and visualized using ethidium bromide (data not shown). Two samples failed to show amplification with the human β-globin (BG) primers; one of these samples was negative by both the HCP LAMP and BG PCR assays, while one sample was positive by BG PCR but negative by HCP LAMP. Furthermore, one sample that was positive by the LAMP assay failed to show amplification with BG primers. Conversely, no fluorescence was observed in the pellet or supernatant fractions of urine samples from healthy individuals. LAMP amplification products from positive urine samples and isolate DNA were visualized on agarose gels and produced similar characteristic patterns (Fig. 1).

**DISCUSSION**

The ability to provide laboratory diagnoses in resource-poor regions remains challenging. Many institutions in the developing world do not have the resources to detect and to identify infectious agents rapidly and precisely (20). In the case of PDH associated with HIV, the need for straightforward and inexpensive laboratory diagnostic tools remains important, because PDH can cause death in 95% of cases (21) within months if it is undiagnosed or
misdiaagnosed. Delayed antifungal treatment of PDH results in mortality rates between 30 and 42% (22–26) in regions where the disease is endemic and where there are underserved populations or limited diagnostic resources. Molecular diagnostic tests have the potential to detect very small amounts of DNA with high specificity, and the LAMP method is both rapid and inexpensive. We developed a LAMP assay to assist in rapid molecular identification of cultured H. capsulatum isolates, as well as to detect H. capsulatum DNA in urine from patients with disseminated disease. Using DNA from cultured isolates, we showed that the Hcp100 LAMP assay could detect less than 30 Histoplasma genomes, a sensitivity 10-fold greater than that of traditional PCR assays. Further, the LAMP assay did not show cross-reactions with DNA of other fungal organisms or with mycobacteria; the latter cause disseminated infections with symptoms nearly identical to those of PDH in persons with HIV/AIDS.

This novel LAMP assay may have two potential applications for the diagnosis of histoplasmosis in limited-resource settings. First, in a pilot validation study, we found that the LAMP assay was more sensitive than traditional PCR assays in detecting Hcp100 DNA in urine, and the LAMP assay showed no cross-reactions with DNA isolated from urine specimens from healthy persons, suggesting that this assay can be useful for direct detection of H. capsulatum DNA in clinical samples. Second, our data demonstrate that the LAMP assay can be used for rapid confirmation of H. capsulatum in culture when the AccuProbe test is not available. The advantages of and caveats for each application are discussed below.

The LAMP method has proven successful in detecting fungal DNA in specimen types in which whole intact organisms are localized. Pneumocystis species DNA has been detected in sputum and bronchiolar lavage (BAL) fluid specimens from patients with pneumonia (27), Paracoccidioides brasilensis DNA has been detected in sputum specimens (28), and Penicillium marneffei DNA has been detected in formalin-fixed, paraffin-embedded (FFPE) tissue specimens (29). In our study, we targeted residual intracellular (in leukocyte debris) and free circulating fungal DNA in urine. Obvious advantages of urine are that sample collection is noninvasive and large quantities can easily be obtained from individual patients. Examination of urine sediment reveals a variety of cells including phagocytes (30), in which H. capsulatum survives by avoidance of lytic digestion (31). Additionally, DNA released from dying fungal cells is known to cross the renal barrier and is subsequently excreted in urine as cell-free DNA in lengths suitable for detection using PCR (32). In fact, urine is now commonly utilized in molecular diagnostic testing, and many organisms that cause systemic infections are detected in this bodily fluid (33–37). We tested urine specimens collected from persons with HIV infection who had culture-proven PDH and positive antigenuria to determine LAMP assay sensitivity. Although an obvious caveat of our study is that only a small number of culture-positive urine specimens were collected from persons with HIV infection and histoplasmosis (n = 6) and from healthy control subjects (n = 10).

### Table 4 Detection of H. capsulatum in human urine specimens using the LAMP assay

<table>
<thead>
<tr>
<th>Urine specimen no.</th>
<th>Health status&lt;sup&gt;a&lt;/sup&gt;</th>
<th>ELISA&lt;sup&gt;b&lt;/sup&gt; antigenuria (ng/µL)</th>
<th>LAMP result&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Human β-globin (PCR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>208</td>
<td>HIV infection, culture-proven histoplasmosis</td>
<td>25.3</td>
<td>+ S, P</td>
<td>+</td>
</tr>
<tr>
<td>209</td>
<td>HIV infection, culture-proven histoplasmosis</td>
<td>12.4</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>260</td>
<td>HIV infection, culture-proven histoplasmosis</td>
<td>13.8</td>
<td>+ P</td>
<td>+</td>
</tr>
<tr>
<td>258</td>
<td>HIV infection, culture-proven histoplasmosis</td>
<td>12.9</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>256</td>
<td>HIV infection, culture-proven histoplasmosis</td>
<td>13.1</td>
<td>+ S, P</td>
<td>+</td>
</tr>
<tr>
<td>548</td>
<td>HIV infection, culture-proven histoplasmosis</td>
<td>12.6</td>
<td>+ S, P</td>
<td>–</td>
</tr>
<tr>
<td>C5</td>
<td>Healthy</td>
<td>0.0</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>C6</td>
<td>Healthy</td>
<td>0.0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>C7</td>
<td>Healthy</td>
<td>0.0</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>C12</td>
<td>Healthy</td>
<td>0.0</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>C13</td>
<td>Healthy</td>
<td>0.0</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>C15</td>
<td>Healthy</td>
<td>0.0</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>C16</td>
<td>Healthy</td>
<td>0.0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>C17</td>
<td>Healthy</td>
<td>0.0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>UP1</td>
<td>Healthy</td>
<td>0.0</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>UP2</td>
<td>Healthy</td>
<td>0.0</td>
<td>–</td>
<td>+</td>
</tr>
</tbody>
</table>

<sup>a</sup> Urine specimens were collected from persons with HIV infection and histoplasmosis (n = 6) and from healthy control subjects (n = 10).

<sup>b</sup> ELISA, enzyme-linked immunosorbent assay.

<sup>c</sup> S, supernatant fraction; P, pellet fraction.

### FIG 1 Hcp100 LAMP assay of DNA from human urine specimens and cultured H. capsulatum. (A) LAMP products were visualized on a 1.75% agarose gel. Characteristic “ladder-type” banding is shown with H. capsulatum antigen-positive urine and cultured H. capsulatum DNA (lanes 3 and 4, respectively), while no DNA amplification was seen after LAMP of healthy control urine (lane 2). Lane M, molecular size marker; lane 1, no-template control. (B) Corresponding tubes were visualized under UV light; fluorescent signals in tubes with antigen-positive urine and cultured H. capsulatum DNA are shown (lanes 3 and 4, respectively). Tube 1, no-template control; tube 2, healthy control urine.
specimens were available for testing, these pilot data demonstrated that 67% of samples (4/6 samples) were positive in the Hcp100 LAMP assay. One of the two urine samples for which negative LAMP results were obtained was also negative with PCR amplification with human β-globin primers, suggesting that no PCR-amplifiable human DNA was present in that sample (Table 4). In our prior experience using FFPE tissue biopsy specimens, we were seldom able to amplify fungal DNA with PCR when the human β-globin locus did not show amplification (38, 39). Human globin DNA could be amplified from a second urine sample that did not react in the LAMP assay. We assume that this sample contained insufficient fungal DNA to be detected even with the sensitive LAMP assay.

We have ruled out the presence of DNA polymerase inhibitors as a cause of insensitivity, since mock-positive urine specimens amplified Hcp100 strongly in both the LAMP and PCR assays. These samples were spiked with H. capsulatum DNA and immediately processed for DNA extraction. All were positive, further suggesting that DNA degradation contributed to decreased sensitivity of LAMP detection in urine. Overall, our data suggest that LAMP can be used to detect H. capsulatum DNA in urine samples; however, a large number of urine samples will need to be tested to determine the sensitivity of this method. In addition, the difficulty of extracting high-quality fungal DNA from clinical specimens using a rapid inexpensive method poses the greatest challenge in making LAMP available as a sustainable diagnostic method for fungal infections in resource-challenged laboratories.

The Hcp100 LAMP assay was highly sensitive in confirming the identification of H. capsulatum from DNA prepared from cultured isolates, a feature that can be helpful in countries with limited resources, where culture of blood and/or bone marrow samples is frequently the primary method for diagnosis of PDH. In these countries, diagnostic confirmation of cultured isolates is frequently made using morphological observations alone, and Histoplasma can be confused with other yeasts of similar size, such as Candida glabrata. Using the Hcp100 LAMP assay, only a small amount of yeast growth is necessary for DNA extraction and confirmation of H. capsulatum in culture.

The purpose of our study was to develop a DNA-based method for detection of disseminated histoplasmosis that could be performed in resource-challenged laboratories. We have shown proof of concept that LAMP may be a valuable tool for detecting disseminated histoplasmosis. Further evaluation of LAMP using fresh-frozen urine, serum, or whole-blood samples is required, and a simpler and less expensive DNA extraction method should be evaluated for use in resource-limited countries.

ACKNOWLEDGMENTS

We thank the Bevier Public Health Summer Internship at Agnes Scott College for providing financial support to Yitian Zhou during her tenure at the Mycotic Diseases Branch of the CDC.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

REFERENCES


